Skip to main content
Home
FULL MENU Close Menu
Home
Home

Zosia Chustecka

News

Increased cancer in military pilots and ground crew: Pentagon

Author:
Zosia Chustecka
Publish date: March 20, 2023

But military aircrew and ground crew were less likely to die from cancer, compared with the U.S. population.

  • Read More

News

Europe approves first gene therapy for hemophilia B

Author:
Zosia Chustecka
Publish date: February 27, 2023

Exorbitantly priced gene therapy to treat hemophilia B has been approved for sale across the European Union and European Economic Area.

  • Read More

News

FDA approves once-weekly hemophilia A product

Author:
Zosia Chustecka
Publish date: February 24, 2023

Newly approved by the FDA, this replacement therapy for a rare bleeding disorder has been found to reduce both dosing frequency and bleeds.

  • Read More

News

FDA approves first-in-class drug for follicular lymphoma

Author:
Zosia Chustecka
Publish date: December 23, 2022

New treatment for relapsed/refractory follicular lymphoma, newly approved by the FDA, showed effectiveness in research presented at ASH 2022.

  • Read More

News

FDA approves olutasidenib for some AML patients

Author:
Zosia Chustecka
Publish date: December 5, 2022

Olutasidenib has been green-lighted by the FDA for treatment of some patients with acute myeloid leukemia.

  • Read More

News

FDA rejects poziotinib for certain types of lung cancer

Author:
Zosia Chustecka
Publish date: December 1, 2022

The clinical data the company submitted was deemed insufficient for approval.

  • Read More

News

Atezolizumab (Tecentriq) bladder cancer indication withdrawn in United States

Author:
Zosia Chustecka
Publish date: December 1, 2022

The anti-PD-L1 inhibitor continues to be approved for lung and liver cancers and melanoma.

  • Read More

News

Blenrep for multiple myeloma withdrawn from U.S. market

Author:
Zosia Chustecka
Publish date: November 22, 2022

As requested by the U.S. Food and Drug Administration, the multiple myeloma drug blenrep is being taken off the market after disappointing results...

  • Read More

News

FDA approves new immunotherapy combo for liver cancer

Author:
Zosia Chustecka
Publish date: October 24, 2022

The Food and Drug Administration has approved a new immunotherapy combination for use in the treatment of...

  • Read More

News

FDA approves futibatinib (Lytgobi) for certain biliary tract cancers

Author:
Zosia Chustecka
Publish date: October 3, 2022

Futibatinib is “a key example of the potential of precision medicine” in intrahepatic cholangiocarcinoma.

  • Read More

News

First drug therapy approved for childhood GVHD

Author:
Zosia Chustecka
Publish date: August 26, 2022

FDA greenlights ibrutinib for child blood cancer patients with chronic graft-versus-host disease.

  • Read More

News

Oncologists’ wealth and debt: COVID had little impact

Author:
Zosia Chustecka
Publish date: August 17, 2022

Oncologists’ income rose, on average, by 2% in the past year and now stands at an average of $411,000 annually.

  • Read More

News

FDA approves Enhertu (trastuzumab deruxtecan) for HER2 lung cancer

Author:
Zosia Chustecka
Publish date: August 12, 2022

“These results establish the new standard of care for patients with NSCLC harboring HER2 mutations.”

  • Read More

News

Oncologists flock to Chicago for ASCO, after 2 years online

Author:
Zosia Chustecka
Publish date: June 3, 2022

The theme of the 2022 meeting is advancing equitable cancer care through innovation.

  • Read More

News

Immunotherapy now first line for esophageal cancer

Author:
Zosia Chustecka
Publish date: May 31, 2022

The “approvals bring two first-line immunotherapy-based treatment options at once ... to newly diagnosed patients with unresectable advanced or...

  • Read More

Pages

  • 1
  • 2
  • 3
  • last »

Privacy Policy

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2023 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close